Current clinical trials of TKI-based therapies in children and adults with Ph-like ALL
| Ph-like ALL alterations . | Kinase inhibitor . | Disease status . | Age, y . | Clinical trial . |
|---|---|---|---|---|
| ABL class | Dasatinib | Newly diagnosed | 1-30 | NCT01406756 (COG AALL1131) |
| ABL class | Dasatinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) |
| ABL class | Dasatinib | Relapsed | ≥10 | NCT02420717 (MDACC) |
| CRLF2/JAK pathway | Ruxolitinib | Newly diagnosed | 1-21 | NCT02723994 (COG AALL1521) |
| CRLF2/JAK pathway | Ruxolitinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) |
| CRLF2/JAK pathway | Ruxolitinib | Relapsed | ≥10 | NCT02420717 (MDACC) |
| Ph-like ALL alterations . | Kinase inhibitor . | Disease status . | Age, y . | Clinical trial . |
|---|---|---|---|---|
| ABL class | Dasatinib | Newly diagnosed | 1-30 | NCT01406756 (COG AALL1131) |
| ABL class | Dasatinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) |
| ABL class | Dasatinib | Relapsed | ≥10 | NCT02420717 (MDACC) |
| CRLF2/JAK pathway | Ruxolitinib | Newly diagnosed | 1-21 | NCT02723994 (COG AALL1521) |
| CRLF2/JAK pathway | Ruxolitinib | Newly diagnosed | 1-18 | NCT03117751 (SJCRH Total XVII) |
| CRLF2/JAK pathway | Ruxolitinib | Relapsed | ≥10 | NCT02420717 (MDACC) |